Poxviral-based prostate-specific antigen vaccine in prostate cancer.
León
Luis
L
Areses
María C
MC
Anido
Urbano
U
Gómez
Antonio
A
Carballo
Ana M
AM
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D049451:Nomograms; D011212:Poxviridae; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen